16Sep/13

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification … – The Herald | HeraldOnline.com

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification …
The Herald | HeraldOnline.com
… 40 4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41 4.5.4 ocrelizumab – F. Hoffman-La Roche 42 4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42 4.5.6 firategrast – GlaxoSmithKline 43 4.5.7 Siponimod (BAF-312) – Novartis AG …

and more »

16Sep/13

Immune system marker tied to improved bone marrow transplant outcomes – EurekAlert (press release)

Immune system marker tied to improved bone marrow transplant outcomes
EurekAlert (press release)
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children’s …
Bone marrow donation touted as a lifesaverChicago Tribune

all 3 news articles »